All In Biotech

Drug Trial Radar · NCT06722417

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

An Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Icalcaprant in Healthy Adult Japanese and Han Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Nov 26, 2024

Primary completion

Jan 17, 2025

Study completion Jan 17, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.

Conditions

  • Healthy Volunteer

Interventions

  • IcalcaprantDrug

    Oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of IcalcaprantTime frame: Up to approximately 6 days
  2. Time to Cmax (Tmax) of IcalcaprantTime frame: Up to approximately 6 days
  3. Terminal Phase Elimination Rate Constant (Beta) of IcalcaprantTime frame: Up to approximately 6 days
  4. Terminal Phase Elimination Half-Life (t1/2) of IcalcaprantTime frame: Up to approximately 6 days
  5. Area under the plasma concentration-time curve from time 0 until the last measurable Concentration (AUCt) of IcalcaprantTime frame: Up to approximately 6 days
  6. Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of IcalcaprantTime frame: Up to approximately 6 days
  7. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 37 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials, LLC /ID# 271323

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.